Selumetinib, a mitogen-activated protein kinase kinase inhibitor, was the first Food and Drug Administration-approved treatment for children with neurofibromatosis type 1-associated inoperable plexiform neurofibromas. We evaluated hematologic effects in 98 ped... ...

请注册登录后继续浏览